Fig. 7

DAC and RSL3 synergistically exert antileukemic activity in the MLL-AF9-transformed murine AML model. (A) The frequencies of GFP⁺ cells were measured in BM mononuclear cells from Ctrl, DAC, RSL3, or DAC + RSL3 (D + R)-treated AML mice (n = 4 for each group). Representative plots (left) and statistical analysis of GFP⁺ cells (right) are shown. (B) The Wright-Giemsa stain showed BM blasts from Ctrl, DAC, RSL3, or D + R-treated AML mice. Representative pictures (left) and statistical analysis of the percentage of BM blasts (right) are shown. Bar scales represent 20 μm. (C and D) Liver and spleen tissues were isolated from Ctrl, DAC, RSL3, or D + R-treated AML mice (n = 4 for each group), and weights were calculated. Representative pictures (left) and statistical analysis of the liver and spleen weights (right) are shown. (E) Representative images of HE staining of liver and spleen tissues from Ctrl, DAC, RSL3, or D + R-treated leukemic mice. Bar scales represent 100 μm for spleen and liver tissues. (F) Overall survival was calculated in Ctrl (n = 6), DAC (n = 5), RSL3 (n = 6), or D + R (n = 7)-treated leukemic mice. (G and H) MDA (G) and GSH amounts (H) were measured in BM GFP⁺ cells isolated from AML mice treated with Ctrl, DAC, RSL3, or D + R (n = 3 for each group). **P < 0.01; ***P < 0.001